Home
→
Browsing by Author

Browsing by Author "Puigvehí, Marc"

Now showing items 1-9 of 9

Diagnostic Accuracy of the Enhanced Liver Fibrosis (ELF®) Score Using HCV-Infected Serum Samples Cryopreserved for up to 25 Years

Puigvehí, Marc; Hernández, Juanjo; Broquetas, Teresa; Coll Estrada, Susanna; Garcia-Retortillo, Montserrat; Cañete Hidalgo, Nuria; Giménez Romaní, Maria Dolors; Garcia, Mar; Bory Ros, Felipe; Salvadó, Margarita; Solà Lamoglia, Ricard; Carrión Rodríguez, José Antonio (Public Library of Science (PLoS), 2016)

INTRODUCTION & AIMS: Cryopreservation of serum samples is a standard procedure for biomedical research in tertiary centers. However, studies evaluating the long-term biological stability of direct liver fibrosis markers ...
Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002-2020)

Haber, Philipp K.; Puigvehí, Marc; Castet, Florian; Lourdusamy, Vennis; Montal, Robert; Tabrizian, Parissa; Buckstein, Michael; Kim, Edward; Villanueva, Augusto; Schwartz, Myron; Llovet, Josep Maria (Elsevier, 2021)

Background & aims: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with a rapidly changing landscape of treatments. In the past 20 years, numerous randomized controlled trials (RCTs) have ...
Follow-up evaluation of patients with liver test abnormalities detected during SARS-CoV2 infection

Canillas, Lidia; Broquetas, Teresa; Carrión Rodríguez, José Antonio; Pagano, Giulia; Soriano, Agnès; Garrido, Esther; Fernández, Rosa; Viu, Ana; Romero, Judit; Díaz,Gemma; Cañete Hidalgo, Nuria; Coll Estrada, Susanna; Naranjo‐Hans, Dolores; Bessa Caserras, Xavier; Garcia-Retortillo, Montserrat; Puigvehí, Marc (Wiley, 2022)

Abnormal liver function tests (A-LFTs) during admission for coronavirus disease-19 (COVID-19) are frequent, but its evolution after COVID-19 resolution remains unexplored. We evaluated factors related to A-LFTs during ...
Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients

Broquetas, Teresa; Garcia-Retortillo, Montserrat; Micó, Miquel; Canillas, Lidia; Puigvehí, Marc; Cañete Hidalgo, Nuria; Coll Estrada, Susanna; Viu, Ana; Hernández, Juan José; Bessa Caserras, Xavier; Carrión Rodríguez, José Antonio (Baishideng Publishing Group, 2020)

Background: Hepatitis B e antigen-negative chronic hepatitis B patients under nucleos(t)ids analogues (NAs) rarely achieve hepatitis B surface antigen (HBsAg) loss. Aim: To evaluate if the addition of pegylated interferon ...
Immunomodulatory effects of lenvatinib plus anti-programmed cell death protein 1 in mice and rationale for patient enrichment in hepatocellular carcinoma

Torrens, Laura; Montironi, Carla; Puigvehí, Marc; Mesropian, Agavni; Leslie, Jack; Haber, Philipp K.; Maeda, Miho; Balaseviciute, Ugne; Willoughby, Catherine E.; Abril-Fornaguera, Jordi; Piqué-Gili, Marta; Torres-Martín, Miguel; Peix, Judit; Geh, Daniel; Ramon-Gil, Erik; Saberi, Behnam; Friedman, Scott L.; Mann, Derek A.; Sia, Daniela; Llovet, Josep Maria (Wiley, 2021)

Background and aims: Lenvatinib is an effective drug in advanced HCC. Its combination with the anti-PD1 (programmed cell death protein 1) immune checkpoint inhibitor, pembrolizumab, has generated encouraging results in ...
Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma

Haber, Philipp K.; Puigvehí, Marc; Llovet, Josep Maria (Elsevier, 2023)

Background & aims: single-agent anti-PD1 checkpoint inhibitors convey outstanding clinical benefits in a small fraction (∼20%) of patients with advanced hepatocellular carcinoma (aHCC) but the molecular mechanisms determining ...
On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty

Broquetas, Teresa; Hernández, Juan José; Garcia-Retortillo, Montserrat; Canillas, Lidia; Puigvehí, Marc; Cañete Hidalgo, Nuria; Coll Estrada, Susanna; Viu, Ana; Garrido, Esther; Micó, Miquel; Bessa Caserras, Xavier; Carrión Rodríguez, José Antonio (Elsevier, 2022)

Background: Nucleos(t)ide analogues withdrawal may improve HBsAg loss rates. However, conditions to select patients are not well established. Aims: to evaluate the impact of HBsAg kinetics before treatment interruption on ...
Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues

Broquetas, Teresa; Garcia-Retortillo, Montserrat; Hernández, Juanjo; Puigvehí, Marc; Cañete Hidalgo, Nuria; Coll Estrada, Susanna; Cabrero Daniel, Beatriz; Giménez Romaní, Maria Dolors; Solà Lamoglia, Ricard; Carrión Rodríguez, José Antonio (Public Library of Science (PLoS), 2017)

BACKGROUND: HBeAg-negative chronic hepatitis B patients require long-term nucleos(t)ide analogues(NAs) because loss of surface antigen (HBsAg) is unusual. Low quantitative HBsAg (qHBsAg) levels can identify patients with ...
Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma

Soria, Anna; Calvo, Mariona; Casas, Meritxell; Vidales, Zara; Muñoz-Martínez, Sergio; Sapena, Victor; Puigvehí, Marc; Canillas, Lidia; Guardeño, Raquel; Gallego, Adolfo; Mínguez, Beatriz; Horta, Diana; Clos, Ariadna; Montoliu, Silvia; Roget, Mercè; Reig, María; Vergara, Mercè (Frontiers, 2022)

Introduction: the first-line treatment for advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab, but its availability is not universal and elderly patients are underrepresented in clinical trials. There ...

Now showing items 1-9 of 9

Search DSpace

Advanced Search

Browse

All of DSpace

My Account

In collaboration with Compliant to Partaking

Browsing by Author "Puigvehí, Marc"

Browsing by Author "Puigvehí, Marc"

Search DSpace

Browse

All of DSpace

My Account